Independent studies have shown that IL-6 is associated with a poor prognosis in breast cancer (Zhang and Adachi, 1999; Salgado et al, 2003) and is capable of supporting tumour growth in stromal-dependent mechanisms (Sasser et al, 2007; Studebaker et al, 2008; Ara et al, 2009). Here, IL6 is linked to breast cancer.